WALTHAM, Mass. and LYON, France, Jan. 15,
2021 /PRNewswire/ -- Thermo Fisher Scientific Inc.,
(NYSE: TMO), the world leader in serving science, and Groupe
Novasep SAS (Novasep), a leading supplier of services and
technologies for the life sciences industry, today announced that
Thermo Fisher has completed the
acquisition of Henogen S.A., Novasep's viral vector manufacturing
business in Belgium for
approximately €725 million in cash.
Novasep's viral vector manufacturing business provides contract
manufacturing services for vaccines and therapies to biotechnology
companies and large biopharma customers. With two locations in
Seneffe and Gosselies, Belgium,
Novasep's viral vector business offers more than 7,000 square
meters of state-of-the-art clinical and commercial manufacturing
capacity. Founded more than 20 years ago, the business has
approximately 400 employees with substantial operational and
technical expertise in a broad range of viral vector classes and
estimated 2020 revenue of €80 million (or approximately
$95 million).
"Novasep's viral vector business is an excellent strategic fit
as Thermo Fisher continues to expand
its capabilities for cell and gene vaccines and therapies
globally," said Michel Lagarde,
executive vice president of Thermo
Fisher. "The addition of their manufacturing capabilities in
Europe complements our four
development and manufacturing sites in North America. In addition, they bring an
incredibly talented team with more than two decades of experience
across a broad range of viral vectors. The combination will
benefit our global customers seeking support and capacity in the
region as well as European customers bringing new medicines to
patients inside and outside of Europe."
Michel Spagnol, president and
chief executive officer of Novasep said, "Thermo Fisher is an outstanding partner for our
viral vector business and its future development. Our diverse
customer base will benefit from the combination of our viral vector
services capabilities with the scale and capabilities of
Thermo Fisher. Our talented
employees will bring deep expertise to an organization that shares
our commitment to providing ground-breaking new medicines to
patients."
The business will be part of the Pharma Services business within
the Laboratory Products and Services Segment.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving
science, with annual revenue exceeding $25
billion. Our Mission is to enable our customers to make the
world healthier, cleaner and safer. Whether our customers are
accelerating life sciences research, solving complex analytical
challenges, improving patient diagnostics and therapies or
increasing productivity in their laboratories, we are here to
support them. Our global team of more than 75,000 colleagues
delivers an unrivaled combination of innovative technologies,
purchasing convenience and pharmaceutical services through our
industry-leading brands, including Thermo Scientific, Applied
Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and
Patheon. For more information, please visit
www.thermofisher.com.
About Novasep
Novasep is a global provider of cost effective and sustainable
manufacturing solutions for life sciences molecules. Novasep's
unique offering includes process development services, purification
equipment and turnkey processes, contract manufacturing and complex
active molecule services for pharmaceutical, biopharmaceutical,
fine chemical, food and functional ingredients as well as
fermentation and chemical commodities industries.
https://www.novasep.com
Safe Harbor Statement
The following constitutes a "Safe Harbor" statement under the
Private Securities Litigation Reform Act of 1995: This press
release contains forward-looking statements that involve a number
of risks and uncertainties. Important factors that could cause
actual results to differ materially from those indicated by
forward-looking statements include risks and uncertainties relating
to: the duration and severity of the COVID-19 pandemic; the need to
develop new products and adapt to significant technological change;
implementation of strategies for improving growth; general economic
conditions and related uncertainties; dependence on customers'
capital spending policies and government funding policies; the
effect of economic and political conditions and exchange rate
fluctuations on international operations; use and protection of
intellectual property; the effect of changes in governmental
regulations; and the effect of laws and regulations governing
government contracts, as well as the possibility that expected
benefits related to recent or pending acquisitions may not
materialize as expected. Additional important factors that could
cause actual results to differ materially from those indicated by
such forward-looking statements are set forth in our most recent
annual report on Form 10-K and subsequent quarterly reports on Form
10-Q, under the caption "Risk Factors," which is on file with the
Securities and Exchange Commission and available in the "Investors"
section of our website under the heading "SEC Filings." While
we may elect to update forward-looking statements at some point in
the future, we specifically disclaim any obligation to do so, even
if estimates change and, therefore, you should not rely on these
forward-looking statements as representing our views as of any date
subsequent to today.
Media Contact Information:
Ron O'Brien
Phone: +1 781-622-1242
E-mail: ron.obrien@thermofisher.com
Investor Contact Information:
Ken Apicerno
Phone: +1 781-622-1294
E-mail: ken.apicerno@thermofisher.com
For Novasep
Agnes Catineau
Phone: +33 7 78 50 95 46
E-mail: Novasep@brunswickgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-acquires-viral-vector-manufacturing-business-from-novasep-301209241.html
SOURCE Thermo Fisher Scientific